NO20070877L - Aryl- og heteroaryl substituerte tetrahydroisoquinoliner og bruk derav for a blokkere gjenopptak av norepinefrin, dopamin og serotonin - Google Patents
Aryl- og heteroaryl substituerte tetrahydroisoquinoliner og bruk derav for a blokkere gjenopptak av norepinefrin, dopamin og serotoninInfo
- Publication number
- NO20070877L NO20070877L NO20070877A NO20070877A NO20070877L NO 20070877 L NO20070877 L NO 20070877L NO 20070877 A NO20070877 A NO 20070877A NO 20070877 A NO20070877 A NO 20070877A NO 20070877 L NO20070877 L NO 20070877L
- Authority
- NO
- Norway
- Prior art keywords
- pyridinyl
- benzooksazolyl
- isoquinolinyl
- norepinephrine
- serotonin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4743—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
- C07D217/04—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
- C07D217/08—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with a hetero atom directly attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
- C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
- C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
- C07D217/16—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
- C07D217/18—Aralkyl radicals
- C07D217/20—Aralkyl radicals with oxygen atoms directly attached to the aromatic ring of said aralkyl radical, e.g. papaverine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Abstract
Forbindelsene ifølge den foreliggende oppfinnelsen er representert ved den kjemiske strukturen som er vist i formel (I) hvor: Karbonatomet betegnet med * er i R- eller S-konfigurasjonen; og X er en kondensert bisyklisk karbosykel eller heterosykel valgt fra gruppen bestående av benzofuranyl, benzo[6]tiofenyl, benzoisotiazolyl, benzoisoksazolyl, indazolyl, indolyl, isoindolyl, indolizinyl, benzoimidazolyl, benzooksazolyl, benzotiazolyl, benzotriazolyl, imidazo[l,2-a]pyridinyl, pyrazolo[l,5-a]pyridinyl, [l,2,4]triazolo[4,3-a]pyridinyl, tieno[2,3-6]pyridinyl, tieno[3,2-b]pyridinyl, lH-pyrrolo[2,3-b]pyridinyl, indenyl, indanyl, dihydrobenzosykloheptenyl, tetrahydrobenzosykloheptenyl, dihydrobenzotiofenyl, dihydrobenzofuranyl, indolinyl, naftyl, tetrahydronaftyl, kinolinyl, isokinolinyl, 4H-kinolizinyl, 9aH-kinolizinyl, kinazolinyl, cinnolinyl, ftalazinyl, kinoksalinyl, benzo[l,2,3]triazinyl, benzo[l,2,4]triazinyl, 2H-kromenyl, 4H-kromenyl og en kondensert bisyklisk karbosykel eller kondensert bisyklisk heterosykel eventuelt substituert med fra 1 til 4 substituenter som definert i R14; og hvor R1, R2, R3, R4, R5, R6, R7, R8 og R14 er som definert her.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US58844804P | 2004-07-15 | 2004-07-15 | |
PCT/US2005/025193 WO2006020049A2 (en) | 2004-07-15 | 2005-07-15 | Aryl-and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20070877L true NO20070877L (no) | 2007-04-16 |
Family
ID=35907927
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20070877A NO20070877L (no) | 2004-07-15 | 2007-02-15 | Aryl- og heteroaryl substituerte tetrahydroisoquinoliner og bruk derav for a blokkere gjenopptak av norepinefrin, dopamin og serotonin |
Country Status (18)
Country | Link |
---|---|
US (7) | US7541357B2 (no) |
EP (1) | EP1778639B1 (no) |
JP (2) | JP5007226B2 (no) |
KR (2) | KR101412339B1 (no) |
CN (2) | CN101119969B (no) |
AU (1) | AU2005274927B2 (no) |
BR (1) | BRPI0513359A (no) |
CA (1) | CA2573271C (no) |
GE (1) | GEP20094640B (no) |
HK (1) | HK1199253A1 (no) |
IL (1) | IL180349A (no) |
MX (1) | MX2007000428A (no) |
NO (1) | NO20070877L (no) |
NZ (1) | NZ552397A (no) |
RU (1) | RU2388751C2 (no) |
UA (1) | UA91341C2 (no) |
WO (1) | WO2006020049A2 (no) |
ZA (1) | ZA200701232B (no) |
Families Citing this family (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2309953C2 (ru) * | 1999-11-03 | 2007-11-10 | Эймр Текнолоджи, Инк. | Арил- и гетероарилзамещенные тетрагидроизохинолины, фармацевтическая композиция и способ лечения на их основе |
KR100821410B1 (ko) * | 2000-07-11 | 2008-04-10 | 에이엠알 테크놀로지, 인크. | 4-페닐 치환된 테트라하이드로이소퀴놀린 및 이의치료학적 용도 |
ZA200701232B (en) * | 2004-07-15 | 2008-08-27 | Amr Technology Inc | Aryl-and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine and serotonin |
US20060111385A1 (en) * | 2004-11-22 | 2006-05-25 | Molino Bruce F | Novel 4-phenyl substituted tetrahydroisoquinolines and therapeutic use thereof |
US20060111394A1 (en) * | 2004-11-22 | 2006-05-25 | Molino Bruce F | Aryl-and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine and serotonin |
US20060111393A1 (en) * | 2004-11-22 | 2006-05-25 | Molino Bruce F | 4-Phenyl substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine and serotonin |
KR20060059728A (ko) * | 2004-11-29 | 2006-06-02 | 삼성에스디아이 주식회사 | 액정 표시 장치 및 그 제조 방법 |
EP1904069B1 (en) | 2005-07-15 | 2018-06-13 | Albany Molecular Research, Inc. | Aryl-and heteroaryl-substituted tetrahydrobenzazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin |
WO2007095756A1 (en) * | 2006-02-27 | 2007-08-30 | Clera Inc. | Novel central-nervous system acting compounds and methods for the treatment of cns disorders |
EP2018863B9 (en) | 2006-05-16 | 2015-02-18 | Takeda Pharmaceutical Company Limited | Fused heterocyclic compound and use thereof |
EP2032558A1 (en) * | 2006-05-31 | 2009-03-11 | F. Hoffmann-Roche AG | Benzazepine derivatives as monoamine reuptake inhibitors |
WO2008077127A2 (en) * | 2006-12-19 | 2008-06-26 | Lavin Thomas N | Use of modafinil to treat restless leg syndrome |
US20100266504A1 (en) | 2007-11-15 | 2010-10-21 | Takahiro Matsumoto | Condensed pyridine derivative and use thereof |
WO2009118765A2 (en) * | 2008-03-28 | 2009-10-01 | Panacea Biotec Limited | Novel monoamine re-uptake inhibitor |
US9156812B2 (en) | 2008-06-04 | 2015-10-13 | Bristol-Myers Squibb Company | Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine |
AR071997A1 (es) * | 2008-06-04 | 2010-07-28 | Bristol Myers Squibb Co | Forma cristalina de 6-((4s)-2-metil-4-(2-naftil)-1,2,3,4-tetrahidroisoquinolin-7-il)piridazin-3-amina |
AR072297A1 (es) | 2008-06-27 | 2010-08-18 | Novartis Ag | Derivados de indol-2-il-piridin-3-ilo, composicion farmaceutica que los comprende y su uso en medicamentos para el tratamiento de enfermedades mediadas por la sintasa aldosterona. |
US8193363B2 (en) * | 2008-08-29 | 2012-06-05 | Astrazeneca Ab | Compounds suitable as precursors to compounds that are useful for imaging amyloid deposits |
KR101685718B1 (ko) * | 2008-12-19 | 2016-12-12 | 제넨테크, 인크. | 헤테로시클릭 화합물 및 사용 방법 |
KR20120034644A (ko) | 2009-05-12 | 2012-04-12 | 알바니 몰레큘라 리써치, 인크. | 아릴, 헤테로아릴, 및 헤테로사이클 치환된 테트라하이드로이소퀴놀린 및 이의 용도 |
CA2760837C (en) * | 2009-05-12 | 2018-04-03 | Albany Molecular Research, Inc. | 7-([1,2,4]triazolo[1,5-.alpha.]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydroisoquinoline and use thereof |
CN102638982B (zh) * | 2009-05-12 | 2015-07-08 | 百时美施贵宝公司 | (S)-7-([1,2,4]三唑并[1,5-a]吡啶-6-基)-4-(3,4-二氯苯基)-1,2,3,4-四氢异喹啉的晶型及其用途 |
JP5763313B2 (ja) * | 2009-09-03 | 2015-08-12 | 富山化学工業株式会社 | 2−(1−ベンゾチオフェン−5−イル)エタノールの製造法 |
EP2606049A4 (en) | 2010-08-17 | 2014-01-08 | Albany Molecular Res Inc | 2,5-METHANO- AND 2,5-ETHANO-TETRAHYDROBENZAZEPINE DERIVATIVES AND USES THEREOF FOR BLOCKING NOREPINEPHRINE, DOPAMINE, AND SEROTONIN REUPTAKE |
US9073881B2 (en) | 2011-09-23 | 2015-07-07 | Hoffmann-La Roche Inc. | Benzoic acid derivatives |
WO2013049263A1 (en) | 2011-09-27 | 2013-04-04 | Bristol-Myers Squibb Company | Substituted bicyclic heteroaryl compounds |
TWI561521B (en) * | 2011-10-14 | 2016-12-11 | Abbvie Inc | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
WO2014055595A1 (en) * | 2012-10-05 | 2014-04-10 | Merck Sharp & Dohme Corp. | Indoline compounds as aldosterone synthase inhibitiors related applications |
US20160022675A1 (en) * | 2013-03-14 | 2016-01-28 | Bristol-Myers Squibb Company | Processes for preparing tetrahydroisoquinolines |
CN104402816A (zh) * | 2014-10-28 | 2015-03-11 | 常州大学 | 一种苯并吡啶甲酸的合成方法 |
SG11201805202VA (en) * | 2016-01-15 | 2018-07-30 | Pfizer | 6,7,8,9-TETRAHYDRO-5H-PYRIDO[2,3-d]AZEPINE DOPAMINE D3 LIGANDS |
JP6908623B2 (ja) * | 2016-04-13 | 2021-07-28 | ユーシービー バイオファルマ エスアールエル | テトラヒドロイソキノリン誘導体 |
EP3512834A4 (en) * | 2016-09-14 | 2020-05-06 | Vanderbilt University | INHIBIT OF BMP SIGNALING, CONNECTIONS, COMPOSITIONS AND USES THEREOF |
WO2018065288A1 (de) | 2016-10-07 | 2018-04-12 | Bayer Cropscience Aktiengesellschaft | 2-[2-phenyl-1-(sulfonylmethyl)vinyl]-imidazo[4,5-b]pyridin-derivate und verwandte verbindungen als schädlingsbekämpfungsmittel im pflanzenschutz |
WO2018130437A1 (de) | 2017-01-10 | 2018-07-19 | Bayer Aktiengesellschaft | Heterocyclen-derivate als schädlingsbekämpfungsmittel |
AU2018208422B2 (en) | 2017-01-10 | 2021-11-11 | Bayer Aktiengesellschaft | Heterocyclene derivatives as pest control agents |
CN107141202A (zh) * | 2017-06-29 | 2017-09-08 | 白银龙铭化工科技有限公司 | 7‑溴‑3,4‑二氢‑1(2h)‑萘酮化合物的合成方法 |
US20210052600A1 (en) | 2017-12-27 | 2021-02-25 | Takeda Pharmaceutical Company Limited | Therapeutic agents for stress urinary incontinence and incotinence of feces |
US11466012B2 (en) * | 2018-01-10 | 2022-10-11 | Allinky Biopharma | Tetrahydroisoquinoline compounds |
EP3863755A4 (en) * | 2018-10-10 | 2022-08-03 | Albert Einstein College of Medicine | BENZOXAZOLE AND RELATED COMPOUNDS USEFUL AS MODULATORS OF CHAPERONE PROTEIN-MEDIATED AUTOPHAGY |
CN109400453B (zh) * | 2018-12-13 | 2021-04-27 | 河南师范大学 | 一种2,6-二溴苯甲醛的制备方法 |
CN117447376A (zh) * | 2019-12-09 | 2024-01-26 | 苏州恩华生物医药科技有限公司 | 连双环结构sigma-1受体抑制剂 |
CN114315796B (zh) * | 2021-12-30 | 2024-03-26 | 中国药科大学 | 用作hpk1激酶抑制剂的化合物及其制备方法和应用 |
Family Cites Families (305)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH527194A (de) | 1970-01-06 | 1972-08-31 | Hoffmann La Roche | Verfahren zur Herstellung von Isochinolin-Derivaten |
US3666763A (en) | 1970-01-06 | 1972-05-30 | Hoffmann La Roche | 4-phenyl isoquinolines and process for preparing same |
US3947456A (en) * | 1970-01-06 | 1976-03-30 | Hoffman-La Roche Inc. | Substituted 4-phenyl isoquinolines |
JPS5223083B2 (no) | 1972-03-31 | 1977-06-22 | ||
JPS5223083Y2 (no) | 1972-06-23 | 1977-05-26 | ||
GB1504424A (en) * | 1975-08-09 | 1978-03-22 | Beecham Group Ltd | Isoquinoline-derived aminoethers |
US4340600A (en) | 1980-05-22 | 1982-07-20 | Smithkline Corporation | Renal dilating methods and compositions using 4-(3,4-dihydroxyphenyl)-1,2,3,4-tetrahydroisoquinolines |
DE3333994A1 (de) | 1983-09-21 | 1985-04-04 | Troponwerke GmbH & Co KG, 5000 Köln | Neue pyridoindolderivate, verfahren zu ihrer herstellung und ihre verwendung |
US4843071A (en) | 1986-12-05 | 1989-06-27 | Serotonin Industries Of Charleston | Method and composition for treating obesity, drug abuse, and narcolepsy |
ZA885824B (en) * | 1987-08-14 | 1989-04-26 | Merrell Dow Pharma | Novel antidepressants |
EP0360390A1 (en) | 1988-07-25 | 1990-03-28 | Glaxo Group Limited | Spirolactam derivatives |
MX18467A (es) | 1988-11-23 | 1993-07-01 | Pfizer | Agentes terapeuticos de quinuclidinas |
FI895821A0 (fi) | 1988-12-07 | 1989-12-05 | Wellcome Found | Farmaceutiskt aktiva cns foereningar. |
US4902710A (en) * | 1988-12-14 | 1990-02-20 | Eli Lilly And Company | Serotonin and norepinephrine uptake inhibitors |
US5114976A (en) | 1989-01-06 | 1992-05-19 | Norden Michael J | Method for treating certain psychiatric disorders and certain psychiatric symptoms |
EP0380223A1 (en) | 1989-01-17 | 1990-08-01 | Konica Corporation | Colour filter and process for producing the same |
JPH02281203A (ja) | 1989-04-21 | 1990-11-16 | Konica Corp | カラーフィルター |
BG49761A1 (en) | 1989-04-24 | 1992-02-14 | Vissh Khim T I | 4- (4'- chalophenyl)- 2- methyl- 1, 2, 3, 4- tetrahydroisohinolines and method for its preparation |
US5164372A (en) | 1989-04-28 | 1992-11-17 | Fujisawa Pharmaceutical Company, Ltd. | Peptide compounds having substance p antagonism, processes for preparation thereof and pharmaceutical composition comprising the same |
AU6368090A (en) | 1989-10-03 | 1991-04-11 | Warner-Lambert Company | Substituted carboxytetrahydroisoquinolines and derivatives thereof having pharmaceutical activity |
IE903957A1 (en) | 1989-11-06 | 1991-05-08 | Sanofi Sa | Aromatic amine compounds, their method of preparation and¹pharmaceutical compositions in which they are present |
FR2654725B1 (fr) | 1989-11-23 | 1992-02-14 | Rhone Poulenc Sante | Nouveaux derives de l'isoindolone, leur preparation et les compositions pharmaceutiques qui les contiennent. |
FR2654726B1 (fr) | 1989-11-23 | 1992-02-14 | Rhone Poulenc Sante | Nouveaux derives de l'isoindolone et leur preparation. |
GB8929070D0 (en) | 1989-12-22 | 1990-02-28 | Fujisawa Pharmaceutical Co | Peptide compounds,processes for preparation thereof and pharmaceutical composition comprising the same |
US5232929A (en) | 1990-11-28 | 1993-08-03 | Pfizer Inc. | 3-aminopiperidine derivatives and related nitrogen containing heterocycles and pharmaceutical compositions and use |
UA41251C2 (uk) | 1990-01-04 | 2001-09-17 | Пфайзер, Інк. | Гідровані азотвмісні гетероциклічні сполуки, похідні піперидину, фармацевтична композиція та спосіб пригнічення активності речовини р в організмі |
WO1991012266A1 (en) | 1990-02-15 | 1991-08-22 | Fujisawa Pharmaceutical Co., Ltd. | Peptide compound |
US5447947A (en) | 1990-02-26 | 1995-09-05 | Arc 1 | Compositions and methods of treatment of sympathetically maintained pain |
ATE113947T1 (de) | 1990-06-01 | 1994-11-15 | Pfizer | 3-amino-2-arylchinuclidine, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen. |
EP0540526B1 (en) | 1990-07-23 | 1994-12-28 | Pfizer Inc. | Quinuclidine derivatives |
EP0550635B1 (en) | 1990-09-28 | 1995-04-19 | Pfizer Inc. | Fused ring analogs of nitrogen containing nonaromatic heterocycles |
GB9023116D0 (en) | 1990-10-24 | 1990-12-05 | Fujisawa Pharmaceutical Co | Peptide compounds,processes for preparation thereof and pharmaceutical composition comprising the same |
JPH04193867A (ja) | 1990-11-23 | 1992-07-13 | Nippon Shinyaku Co Ltd | イソキノリノール誘導体及び医薬 |
ATE129409T1 (de) | 1990-12-21 | 1995-11-15 | Fujisawa Pharmaceutical Co | Neue verwendung von peptidderivat. |
HUT65612A (en) | 1991-01-10 | 1994-07-28 | Pfizer | Process n-alcyl-quinuclidinium salts of p-antagonistic activity |
DE69220258T2 (de) | 1991-02-11 | 1997-12-18 | Merck Sharp & Dohme | Azabicyclische Verbindungen, diese enthaltende pharmazeutische Zubereitungen und ihre therapeutische Verwendung |
ES2065175T3 (es) | 1991-03-01 | 1995-02-01 | Pfizer | Derivados de 1-azabiciclo(3.2.2)nonan-3-amina. |
BR9205807A (pt) | 1991-03-26 | 1994-06-28 | Pfizer | Preparação estéreo-seletiva de piperidinas substituidas |
FR2677361A1 (fr) | 1991-06-04 | 1992-12-11 | Adir | Nouveaux peptides et pseudopeptides, derives de tachykinines, leur procede de preparation et les compositions pharmaceutiques qui les contiennent. |
FR2676053B1 (fr) | 1991-05-03 | 1993-08-27 | Sanofi Elf | Nouveaux composes dialkylenepiperidino et leurs enantiomeres, procede pour leur preparation et compositions pharmaceutiques les contenant. |
FR2676055B1 (fr) | 1991-05-03 | 1993-09-03 | Sanofi Elf | Composes polycycliques amines et leurs enantiomeres, procede pour leur preparation et compositions pharmaceutiques les contenant. |
FR2676442B1 (fr) | 1991-05-17 | 1993-08-06 | Rhone Poulenc Rorer Sa | Nouveau derives de perhydroisoindole, leur preparation et les compositions pharmaceutiques qui les contiennent. |
FR2676447B1 (fr) | 1991-05-17 | 1993-08-06 | Rhone Poulenc Rorer Sa | Nouveaux derives du thiopyranopyrrole et leur preparation. |
FR2676443B1 (fr) | 1991-05-17 | 1993-08-06 | Rhone Poulenc Rorer Sa | Nouveaux derives de perhydroisoindole et leur preparation. |
FR2676446B1 (fr) | 1991-05-17 | 1993-08-06 | Rhone Poulenc Rorer Sa | Nouveaux derives du thiopyranopyrrole, leur preparation et les compositions pharmaceutiques qui les contiennent. |
HUT65771A (en) | 1991-05-22 | 1994-07-28 | Pfizer | Process for producing substituted 3-amino-quinuclidine derivatives and pharmaceutical compositions containing them |
WO1992020661A1 (en) | 1991-05-22 | 1992-11-26 | Merck & Co., Inc. | N, n-diacylpiperazines |
UA27776C2 (uk) | 1991-05-31 | 2000-10-16 | Пфайзер Інк. | Похідні хінуклідину та їх фармацевтично прийнятні солі, що є антагоністами речовини р у ссавців, фармацевтична композиція, що має антагоністичну дію на речовину р у ссавців |
GB9113219D0 (en) | 1991-06-19 | 1991-08-07 | Fujisawa Pharmaceutical Co | Peptide compound,processes for preparation thereof and pharmaceutical composition comprising the same |
KR0154882B1 (ko) | 1991-06-20 | 1998-11-16 | 알렌 제이. 스피겔 | 질소 함유 헤테로사이클릭 화합물의 플루오로알콕시벤질아미노 유도체 |
TW202432B (no) | 1991-06-21 | 1993-03-21 | Pfizer | |
US5288730A (en) | 1991-06-24 | 1994-02-22 | Merck Sharp & Dohme Limited | Azabicyclic compounds, pharmaceutical compositions containing them and their use in therapy |
CA2110513A1 (en) | 1991-07-05 | 1993-01-21 | Christopher J. Swain | Aromatic compounds, pharmaceutical compositions containing them and their use in therapy |
EP0536817A1 (en) | 1991-07-05 | 1993-04-14 | MERCK SHARP & DOHME LTD. | Azabicyclic compounds as tachykinin antagonists |
WO1993001169A2 (en) | 1991-07-05 | 1993-01-21 | Merck Sharp & Dohme Limited | Aromatic compounds, pharmaceutical compositions containing them and their use in therapy |
ATE133658T1 (de) | 1991-07-10 | 1996-02-15 | Merck Sharp & Dohme | Aromatische verbindungen diese enthaltende pharmazeutische zusammensetzungen und ihre therapeutische verwendung |
WO1993001159A1 (en) | 1991-07-10 | 1993-01-21 | Merck Sharp & Dohme Limited | Fused tricyclic compounds, pharmaceutical compositions containing them and their use in therapy |
MY110227A (en) | 1991-08-12 | 1998-03-31 | Ciba Geigy Ag | 1-acylpiperindine compounds. |
EP0600952B1 (en) | 1991-08-20 | 1996-04-17 | MERCK SHARP & DOHME LTD. | Azacyclic compounds, processes for their preparation and pharmaceutical compositions containing them |
EP1082959A1 (en) | 1991-09-20 | 2001-03-14 | Glaxo Group Limited | NK1 Antagonists for the treatment of depression |
US5527808A (en) | 1991-09-26 | 1996-06-18 | Pfizer Inc. | Fused tricyclic nitrogen containing heterocycles |
WO1993009116A1 (en) | 1991-11-07 | 1993-05-13 | Yoshitomi Pharmaceutical Industries, Ltd. | Quinuclidine compound and medicinal use thereof |
DK0613458T3 (da) | 1991-11-12 | 1998-02-09 | Pfizer | Acykliske ethylendiaminderivater som substans P receptorantagonister |
EP0545478A1 (en) | 1991-12-03 | 1993-06-09 | MERCK SHARP & DOHME LTD. | Heterocyclic compounds as tachykinin antagonists |
GB9200535D0 (en) | 1992-01-10 | 1992-02-26 | Fujisawa Pharmaceutical Co | New compound |
GB9201179D0 (en) | 1992-01-21 | 1992-03-11 | Glaxo Group Ltd | Chemical compounds |
US5241065A (en) | 1992-02-25 | 1993-08-31 | Schering Corporation | 2,3,4,5-tetrahydro-1h-3-benzazepines having anti-psychotic activity |
US5328927A (en) | 1992-03-03 | 1994-07-12 | Merck Sharpe & Dohme, Ltd. | Hetercyclic compounds, processes for their preparation and pharmaceutical compositions containing them |
US5595872A (en) | 1992-03-06 | 1997-01-21 | Bristol-Myers Squibb Company | Nucleic acids encoding microsomal trigyceride transfer protein |
JP2656702B2 (ja) | 1992-03-23 | 1997-09-24 | ファイザー製薬株式会社 | ペプチド性キヌクリジン |
FR2689888B1 (fr) | 1992-04-10 | 1994-06-10 | Rhone Poulenc Rorer Sa | Nouveaux derives de perhydroisoindole, leur preparation et les compositions pharmaceutiques qui les contiennent. |
WO1993021181A1 (en) | 1992-04-15 | 1993-10-28 | Merck Sharp & Dohme Limited | Azacyclic compounds |
GB2266529A (en) | 1992-05-01 | 1993-11-03 | Merck Sharp & Dohme | Tetrahydroisoquinoline derivatives |
CA2134964C (en) | 1992-05-18 | 1997-12-30 | Manoj C. Desai | Bridged aza-bicyclic derivatives as substance p antagonists |
GB9211193D0 (en) | 1992-05-27 | 1992-07-08 | Merck Sharp & Dohme | Therapeutic agents |
CA2099233A1 (en) | 1992-06-29 | 1993-12-30 | Conrad P. Dorn | Morpholine and thiomorpholine tachykinin receptor antagonists |
US5612336A (en) | 1992-07-13 | 1997-03-18 | Merck, Sharp & Dohme Ltd. | Heterocyclic amide derivatives as tachykinin antagonists |
EP0786522A2 (en) | 1992-07-17 | 1997-07-30 | Ribozyme Pharmaceuticals, Inc. | Enzymatic RNA molecules for treatment of stenotic conditions |
GB2268931A (en) | 1992-07-22 | 1994-01-26 | Merck Sharp & Dohme | Azabicyclic tachykinin-receptor antagonists |
ATE173725T1 (de) | 1992-07-28 | 1998-12-15 | Merck Sharp & Dohme | Azazyklische verbindungen |
GB2269170A (en) | 1992-07-29 | 1994-02-02 | Merck Sharp & Dohme | Azatricyclic tachykinin antagonists |
WO1994003429A1 (en) | 1992-07-31 | 1994-02-17 | Merck Sharp & Dohme Limited | Substituted amines as tachykinin receptor antagonists |
JPH07506379A (ja) | 1992-08-04 | 1995-07-13 | ファイザー・インコーポレーテッド | 物質p受容体アンタゴニストとしての3−ベンジルアミノ−2−フェニル−ピペリジン |
GB9216911D0 (en) | 1992-08-10 | 1992-09-23 | Merck Sharp & Dohme | Therapeutic agents |
PT655055E (pt) | 1992-08-13 | 2001-03-30 | Warner Lambert Co | Antagonistas de taquiquinina |
US5212185A (en) | 1992-08-14 | 1993-05-18 | G. D. Searle & Co. | Piperidinyl-terminated alkylamino ethynyl alanine amino diol compounds for treatment of hypertension |
US5721255A (en) | 1992-08-19 | 1998-02-24 | Pfizer Inc. | Substituted benzylamino nitrogen containing non-aromatic heterocycles |
US5482967A (en) | 1992-09-04 | 1996-01-09 | Takeda Chemical Industries, Ltd. | Condensed heterocyclic compounds, their production and use |
AU4973693A (en) | 1992-09-10 | 1994-03-29 | Merck Sharp & Dohme Limited | Alcohols and ethers with aromatic substituents as tachykinin-antagonists |
GB9220286D0 (en) | 1992-09-25 | 1992-11-11 | Merck Sharp & Dohme | Therapeutic agents |
GB2271566A (en) | 1992-10-14 | 1994-04-20 | Merck & Co Inc | HIV integrase inhibitors |
JP2656699B2 (ja) | 1992-10-21 | 1997-09-24 | ファイザー製薬株式会社 | 置換ベンジルアミノキヌクリジン |
GB9222262D0 (en) | 1992-10-23 | 1992-12-09 | Merck Sharp & Dohme | Therapeutic agents |
GB9222486D0 (en) | 1992-10-26 | 1992-12-09 | Merck Sharp & Dohme | Therapeutic agents |
EP0666856B1 (en) | 1992-10-28 | 2000-01-05 | MERCK SHARP & DOHME LTD. | 4-arylmethyloxymethyl piperidines as tachykinin antagonists |
JP2656700B2 (ja) | 1992-10-28 | 1997-09-24 | ファイザー製薬株式会社 | 置換キヌクリジン誘導体 |
WO1994010167A1 (en) | 1992-10-30 | 1994-05-11 | Merck Sharp & Dohme Limited | Tachykinin antagonists |
ES2096312T3 (es) | 1992-11-12 | 1997-03-01 | Pfizer | Derivado de quinuclidina como antagonista de la sustancia p. |
US5261188A (en) | 1992-11-23 | 1993-11-16 | The Standard Products Company | Belt weatherstrip with bulb |
JPH06153997A (ja) | 1992-11-27 | 1994-06-03 | Canon Inc | 検出信号増幅による標的核酸の検出方法 |
WO1994013663A1 (en) | 1992-12-10 | 1994-06-23 | Pfizer Inc. | Aminomethylene substituted non-aromatic heterocycles and use as substance p antagonists |
EP0673367A1 (en) | 1992-12-14 | 1995-09-27 | MERCK SHARP & DOHME LTD. | 4-aminomethyl/thiomethyl/sulfonylmethyl-4-phenylpiperidines as tachykinin receptor antagonists |
GB9226581D0 (en) | 1992-12-21 | 1993-02-17 | Merck Sharp & Dohme | Therapeutic agents |
DK154192D0 (da) * | 1992-12-23 | 1992-12-23 | Neurosearch As | Heterocycliske forbindelser |
GB9300051D0 (en) | 1993-01-04 | 1993-03-03 | Merck Sharp & Dohme | Therapeutic agents |
EP0610793A1 (en) | 1993-02-08 | 1994-08-17 | Takeda Chemical Industries, Ltd. | Tetracyclic morpholine derivatives and their use or analgesics |
US5633266A (en) | 1993-02-18 | 1997-05-27 | Merck Sharp & Dohme Ltd. | Azacyclic compounds compositions containing them and their use as tachykinin antagonists |
AU6140694A (en) | 1993-02-22 | 1994-09-14 | Merck Sharp & Dohme Limited | Aromatic compounds, compositions containing them and their use in therapy |
ATE166650T1 (de) | 1993-03-04 | 1998-06-15 | Pfizer | Spiroazacyclischderivate als substanz p antagonisten |
KR100238346B1 (ko) | 1993-04-07 | 2000-03-02 | 오쓰까 아끼히꼬 | 피페리딘 유도체를 유효성분으로 하는 말초혈관확장제 |
DK0696280T3 (da) | 1993-05-06 | 1998-01-12 | Merrell Pharma Inc | Substituerede pyrrolidin-3-yl-alkyl-piperidiner anvendelige som tachykinin-antagonister |
IL109646A0 (en) | 1993-05-19 | 1994-08-26 | Pfizer | Heteroatom substituted alkyl benzylamino-quinuclidines |
EP0702681A1 (en) | 1993-06-07 | 1996-03-27 | Merck & Co. Inc. | Spiro-substituted azacycles as neurokinin antagonists |
EP0634402A1 (en) | 1993-07-14 | 1995-01-18 | Takeda Chemical Industries, Ltd. | Isochinolinone derivatives, their production and use |
ES2121213T3 (es) | 1993-07-15 | 1998-11-16 | Pfizer | Benciloxiquinuclidinas como antagonistas de la sustancia p. |
TW365603B (en) | 1993-07-30 | 1999-08-01 | Rhone Poulenc Rorer Sa | Novel perhydroisoindole derivatives, their preparation and pharmaceutical compositions which contain them |
GB9315808D0 (en) | 1993-07-30 | 1993-09-15 | Merck Sharp & Dohme | Therapeutic agents |
GB9317987D0 (en) | 1993-08-26 | 1993-10-13 | Glaxo Group Ltd | Chemical compounds |
PT719253E (pt) | 1993-09-17 | 2004-07-30 | Pfizer | Piperidinas 3-amino-5-carboxi-substituidas e pirrolidinas 3-amino-4-carboxi-substituidas como antagonistas de taquicinina |
WO1995007908A1 (en) | 1993-09-17 | 1995-03-23 | Pfizer Inc. | Heteroarylamino and heteroarylsulfonamido substituted 3-benzylaminomethyl piperidines and related compounds |
IS4208A (is) | 1993-09-22 | 1995-03-23 | Glaxo Group Limited | 3-(tetrazólýl-benzyl)amínó-piperadidín afleiður |
WO1995011880A1 (en) | 1993-10-27 | 1995-05-04 | Merck Sharp & Dohme Limited | Substituted amides as tachykinin antagonists |
US6403577B1 (en) | 1993-11-17 | 2002-06-11 | Eli Lilly And Company | Hexamethyleneiminyl tachykinin receptor antagonists |
IT1271462B (it) | 1993-12-03 | 1997-05-28 | Menarini Farma Ind | Antagonisti delle tachichinine,procedimento per la loro preparazione e loro impiego in formulazioni farmaceutiche. |
IL111960A (en) | 1993-12-17 | 1999-12-22 | Merck & Co Inc | Morpholines and thiomorpholines their preparation and pharmaceutical compositions containing them |
AU1339795A (en) | 1993-12-21 | 1995-07-10 | Eli Lilly And Company | Non-peptide tachykinin receptor antagonists |
PL181214B1 (pl) | 1993-12-29 | 2001-06-29 | Merck Sharp & Dohme | Podstawione związki morfolinowe, sposób ich wytwarzania oraz zawierające je kompozycje farmaceutyczne |
US5854239A (en) | 1993-12-29 | 1998-12-29 | Pfizer Inc. | Diazabicyclic neuokinin antagonists |
US5728716A (en) | 1994-01-28 | 1998-03-17 | Merck Sharp & Dohme Limited | Aralkylamino substituted azacyclic therapeutic agents |
GB9402688D0 (en) | 1994-02-11 | 1994-04-06 | Merck Sharp & Dohme | Therapeutic agents |
US5610165A (en) | 1994-02-17 | 1997-03-11 | Merck & Co., Inc. | N-acylpiperidine tachykinin antagonists |
IL112778A0 (en) | 1994-03-04 | 1995-05-26 | Merck & Co Inc | Substituted heterocycles, their preparation and pharmaceutical compositions containing them |
FR2718136B1 (fr) | 1994-03-29 | 1996-06-21 | Sanofi Sa | Composés aromatiques aminés, procédé pour leur obtention et compositions pharmaceutiques les contenant. |
US5610145A (en) | 1994-04-15 | 1997-03-11 | Warner-Lambert Company | Tachykinin antagonists |
US5607939A (en) | 1994-04-28 | 1997-03-04 | Takeda Chemical Industries, Ltd. | Condensed heterocyclic compounds, their production and use |
ZA953311B (en) | 1994-04-29 | 1996-10-24 | Lilly Co Eli | Non-peptidyl tachykinin receptor antagonists |
EP0758329A1 (en) | 1994-05-05 | 1997-02-19 | MERCK SHARP & DOHME LTD. | Morpholine derivatives and their use as antagonists of tachikinins |
SK142696A3 (en) | 1994-05-07 | 1997-06-04 | Boehringer Ingelheim Kg | Amino acids derivative, method for preparation thereof, pharmaceutical compositions containing said compounds (ii) and their use |
JPH10501228A (ja) | 1994-06-06 | 1998-02-03 | ワーナー−ランバート・コンパニー | タキキニン(nk▲下1▼)受容体アンタゴニスト |
EP0686629A3 (en) | 1994-06-10 | 1999-02-10 | Eli Lilly And Company | Cyclohexyl tachykinine receptor antagonists |
CA2134038C (en) * | 1994-06-16 | 1997-06-03 | David Taiwai Wong | Potentiation of drug response |
MX9700271A (es) | 1994-07-12 | 1997-05-31 | Lilly Co Eli | Antagonistas heterociclicos del receptor de taquinicina. |
DE4425612A1 (de) | 1994-07-20 | 1996-04-04 | Bayer Ag | 6-gliedrige stickstoffhaltige Heteroaryl-oxazolidinone |
HUT76639A (en) | 1994-07-20 | 1997-10-28 | Byk Gulden Lomberg Chem Fab | Pyridyl-thio-compounds, process for producing them and their use |
CA2154116A1 (en) | 1994-07-22 | 1996-01-23 | Philip Arthur Hipskind | 1-aryl-2-acetamidopentanone derivatives for use as tachykinin receptor antagonists |
GB9415997D0 (en) | 1994-08-08 | 1994-09-28 | Merck Sharp & Dohme | Therapeutic agents |
GB9415996D0 (en) | 1994-08-08 | 1994-09-28 | Merck Sharp & Dohme | Therapeutic agents |
TW432061B (en) | 1994-08-09 | 2001-05-01 | Pfizer Res & Dev | Lactams |
DK0777659T3 (da) | 1994-08-15 | 2001-09-03 | Merck Sharp & Dohme | Morpholinderivater og deres anvendelse som terapeutiske midler |
KR100362620B1 (ko) | 1994-08-25 | 2003-02-14 | 메렐 파마슈티칼스 인크. | 알레르기성질환치료에유용한치환된피페리딘,이를포함하는약제학적조성물및이의제조방법 |
DE69405864T2 (de) | 1994-08-29 | 1998-03-26 | Akzo Nobel Nv | Verfahren zur Herstellung von quaternären Diestern |
GB9417956D0 (en) | 1994-09-02 | 1994-10-26 | Merck Sharp & Dohme | Therapeutic agents |
GB9418545D0 (en) | 1994-09-15 | 1994-11-02 | Merck Sharp & Dohme | Therapeutic agents |
US5457107A (en) | 1994-09-16 | 1995-10-10 | Merck & Co., Inc. | Polymorphic form of a tachykinin receptor antagonist |
JPH10506399A (ja) | 1994-09-30 | 1998-06-23 | ノバルティス アクチェンゲゼルシャフト | 1−アシル−4−マリファチルアミノピペリジン化合物 |
TW397825B (en) | 1994-10-14 | 2000-07-11 | Novartis Ag | Aroyl-piperidine derivatives |
FR2725986B1 (fr) | 1994-10-21 | 1996-11-29 | Adir | Nouveaux derives de piperidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
EP0709375B1 (en) | 1994-10-25 | 2005-05-18 | AstraZeneca AB | Therapeutic heterocycles |
GB9421709D0 (en) | 1994-10-27 | 1994-12-14 | Zeneca Ltd | Therapeutic compounds |
CA2162786A1 (en) | 1994-11-22 | 1996-05-23 | Philip Arthur Hipskind | Heterocyclic tachykinin receptor antagonists |
FR2727411B1 (fr) | 1994-11-30 | 1997-01-03 | Rhone Poulenc Rorer Sa | Nouveaux derives de perhydroisoindole, leur preparation et les compositions pharmaceutiques qui les contiennent |
IL116323A0 (en) | 1994-12-13 | 1996-03-31 | Sandoz Ag | Tachykinin antagonists their preparation and pharmaceutical compositions containing them |
GB9426103D0 (en) | 1994-12-23 | 1995-02-22 | Merck Sharp & Dohme | Therapeutic agents |
JP3925662B2 (ja) | 1995-01-12 | 2007-06-06 | グラクソ,グループ,リミテッド | タキキニンアンタゴニスト活性を有するピペリジン誘導体 |
FR2729951B1 (fr) | 1995-01-30 | 1997-04-18 | Sanofi Sa | Nouveaux composes heterocycliques, procede pour leur preparation et compositions pharmaceutiques en contenant |
GB9505492D0 (en) | 1995-03-18 | 1995-05-03 | Merck Sharp & Dohme | Therapeutic agents |
GB9505491D0 (en) | 1995-03-18 | 1995-05-03 | Merck Sharp & Dohme | Therapeutic agents |
US5554641A (en) | 1995-03-20 | 1996-09-10 | Horwell; David C. | Nonpeptides as tachykinin antagonists |
GB9505692D0 (en) | 1995-03-21 | 1995-05-10 | Glaxo Group Ltd | Chemical compounds |
TW394773B (en) | 1995-03-24 | 2000-06-21 | Takeda Chemical Industries Ltd | Cyclic compounds for antagonizing tachykinin receptor, substance p receptor and neurokinin a receptor, their production and pharmaceutical composition |
US5565568A (en) | 1995-04-06 | 1996-10-15 | Eli Lilly And Company | 2-acylaminopropanamides as tachykinin receptor antagonists |
ES2224164T3 (es) | 1995-04-13 | 2005-03-01 | Aventis Pharmaceuticals Inc. | Nuevos derivados de piperazina sustituida que tienen actividad como antagonistas de los receptores de taququinina. |
WO1996037489A1 (en) | 1995-05-25 | 1996-11-28 | Fujisawa Pharmaceutical Co., Ltd. | 1-benzoyl-2-(indolyl-3-alkyl)-piperazine derivatives as neurokinin receptor antagonists |
US5654316A (en) | 1995-06-06 | 1997-08-05 | Schering Corporation | Piperidine derivatives as neurokinin antagonists |
US5817832A (en) | 1995-06-22 | 1998-10-06 | Ciba Specialty Chemicals Corporation | Blue diketopyrrolopyrrole pigments |
GB9513117D0 (en) | 1995-06-28 | 1995-08-30 | Merck Sharp & Dohme | Therapeutic agents |
GB9513121D0 (en) | 1995-06-28 | 1995-08-30 | Merck Sharp & Dohme | Therapeutic agents |
GB9513118D0 (en) | 1995-06-28 | 1995-08-30 | Merck Sharp & Dohme | Therapeutic agents |
JP3042894B2 (ja) | 1995-07-07 | 2000-05-22 | ファイザー製薬株式会社 | サブスタンスpアンタゴニストとしての置換ベンゾラクタム化合物 |
TW340842B (en) | 1995-08-24 | 1998-09-21 | Pfizer | Substituted benzylaminopiperidine compounds |
EP0858444A4 (en) | 1995-10-18 | 1999-12-01 | Merck & Co Inc | CYCLOPENTYL-TACHYKININ RECEPTOR ANTAGONISTS |
DE19541283A1 (de) | 1995-11-06 | 1997-05-07 | Boehringer Ingelheim Kg | Neue Aminosäurederivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen |
GB9523244D0 (en) | 1995-11-14 | 1996-01-17 | Merck Sharp & Dohme | Therapeutic agents |
EP1019410A1 (en) | 1995-11-23 | 2000-07-19 | MERCK SHARP & DOHME LTD. | Spiro-piperidine derivatives and their use as tachykinin antagonists |
GB9524157D0 (en) | 1995-11-25 | 1996-01-24 | Pfizer Ltd | Therapeutic agents |
HU224225B1 (hu) | 1995-12-01 | 2005-06-28 | Sankyo Co. Ltd. | Tachikinin receptor antagonista hatású heterociklusos vegyületek, ezek előállítási eljárása és alkalmazásuk gyógyszerkészítmények előállítására |
GB9525296D0 (en) | 1995-12-11 | 1996-02-07 | Merck Sharp & Dohme | Therapeutic agents |
ZA9610738B (en) | 1995-12-22 | 1997-06-24 | Warner Lambert Co | Subtype selective nmda receptor ligands and the use thereof |
US6025355A (en) | 1997-05-19 | 2000-02-15 | Cambridge Neuroscience, Inc. | Pharmaceutically active compounds and methods of use |
CA2249615A1 (en) | 1996-04-03 | 1997-10-09 | Robert Gomez | Inhibitors of farnesyl-protein transferase |
US5885983A (en) | 1996-05-10 | 1999-03-23 | Bristol-Myers Squibb Company | Inhibitors of microsomal triglyceride transfer protein and method |
US5827875A (en) | 1996-05-10 | 1998-10-27 | Bristol-Myers Squibb Company | Inhibitors of microsomal triglyceride transfer protein and method |
EA001574B1 (ru) | 1996-06-21 | 2001-06-25 | Мерк Шарп Энд Домэ Лимитед | Производные спиропиперидина и их использование в качестве терапевтических агентов |
DE19638486A1 (de) | 1996-09-20 | 1998-03-26 | Basf Ag | Hetaroylderivate |
DE19638484A1 (de) | 1996-09-20 | 1998-03-26 | Basf Ag | Hetaroylderivate |
WO1998035939A1 (fr) | 1997-02-18 | 1998-08-20 | Sanwa Kagaku Kenkyusho Co., Ltd. | Derives de diamide malonique et utilisation de ces derniers |
US5907041A (en) | 1997-03-12 | 1999-05-25 | Rhone-Poulenc Inc. | Process for preparing pyrazole derivatives |
JPH10292008A (ja) | 1997-04-21 | 1998-11-04 | Grand Polymer:Kk | α−オレフィンの重合方法 |
EP1023265B1 (en) | 1997-10-07 | 2003-01-15 | Boehringer Ingelheim (Canada) Ltd. | Azetidinone derivatives for the treatment of hcmv infections |
EP1021404B1 (en) | 1997-10-07 | 2003-01-08 | Boehringer Ingelheim (Canada) Ltd. | Azetidinone derivatives for the treatment of hcmv infections |
US7041702B1 (en) | 1997-10-21 | 2006-05-09 | Scion Pharmaceuticals, Inc. | Pharmaceutically active compounds and methods of use |
US6121261A (en) | 1997-11-19 | 2000-09-19 | Merck & Co., Inc. | Method for treating attention deficit disorder |
US6943159B1 (en) | 1998-02-18 | 2005-09-13 | Neurosearch A/S | Compounds and their use as positive AMPA receptor modulators |
US6043253A (en) | 1998-03-03 | 2000-03-28 | Merck & Co., Inc. | Fused piperidine substituted arylsulfonamides as β3-agonists |
WO2000014076A1 (en) | 1998-09-04 | 2000-03-16 | Ciba Specialty Chemicals Holding Inc. | Process for making 2,4-dihydroxyphenyl and 2-hydroxy-4-alkoxyphenyl substituted triazine compounds |
JP2000186110A (ja) | 1998-12-21 | 2000-07-04 | Ube Ind Ltd | エチレン共重合体の製造方法 |
PT1140761E (pt) | 1999-01-12 | 2004-02-27 | Clariant Finance Bvi Ltd | Benzofenonas e sua utilizacao como foto-iniciadores |
US6664293B2 (en) | 1999-02-26 | 2003-12-16 | Fujiwawa Pharmaceutical Co., Ltd. | Amide compounds for the potentiation of cholinergic activity |
US6586447B1 (en) | 1999-04-01 | 2003-07-01 | Pfizer Inc | 3,3-disubstituted-oxindole derivatives useful as anticancer agents |
JP2001026580A (ja) | 1999-05-10 | 2001-01-30 | Sumitomo Chem Co Ltd | 光学活性1−アリール−1,2,3,4−テトラヒドロイソキノリン類の製造法 |
US6562836B1 (en) | 1999-05-24 | 2003-05-13 | Queen's University Of Kingston | Methods and compounds for inhibiting amyloid deposits |
AU5567000A (en) | 1999-06-24 | 2001-01-09 | Toray Industries, Inc. | Alpha1b-adrenergic receptor antagonists |
AU5994900A (en) | 1999-07-09 | 2001-01-30 | Isis Innovation Limited | Compounds for inhibiting diseases and preparing cells for transplantation |
US6340681B1 (en) | 1999-07-16 | 2002-01-22 | Pfizer Inc | 2-benzimidazolylamine compounds as ORL-1-receptor agonists |
JP2001086110A (ja) | 1999-09-13 | 2001-03-30 | Toyo Commun Equip Co Ltd | 暗号化情報のパケット通信システム |
RU2309953C2 (ru) * | 1999-11-03 | 2007-11-10 | Эймр Текнолоджи, Инк. | Арил- и гетероарилзамещенные тетрагидроизохинолины, фармацевтическая композиция и способ лечения на их основе |
NZ519146A (en) * | 1999-11-03 | 2004-02-27 | Albany Molecular Res Inc | 4-phenyl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine and serotonin |
US7163949B1 (en) | 1999-11-03 | 2007-01-16 | Amr Technology, Inc. | 4-phenyl substituted tetrahydroisoquinolines and use thereof |
WO2001051919A2 (en) | 2000-01-07 | 2001-07-19 | Transform Pharmaceuticals, Inc. | High-throughput formation, identification, and analysis of diverse solid-forms |
AU2001262150A1 (en) | 2000-03-23 | 2001-10-03 | Mitsubishi Pharma Corporation | 2-(nitrogen-heterocyclic)pyrimidone derivatives |
AU5499401A (en) | 2000-05-15 | 2001-11-26 | Darwin Discovery Limited | Hydroxamic and carboxylic acid derivatives having mmp and tnf inhibitory activity |
US6664256B1 (en) | 2000-07-10 | 2003-12-16 | Kowa Co., Ltd. | Phenylpyridazine compounds and medicines containing the same |
KR100821410B1 (ko) | 2000-07-11 | 2008-04-10 | 에이엠알 테크놀로지, 인크. | 4-페닐 치환된 테트라하이드로이소퀴놀린 및 이의치료학적 용도 |
EP1341765A1 (en) | 2000-12-07 | 2003-09-10 | AstraZeneca AB | Therapeutic compounds |
US6506772B1 (en) | 2000-12-15 | 2003-01-14 | Hoffmann-La Roche Inc. | Substituted [1,2,4]triazolo[1,5a]pyridine derivatives with activity as adenosine receptor ligands |
US6900220B2 (en) | 2001-01-02 | 2005-05-31 | Syntex (U.S.A.) Llc | Quinazolone derivatives as alpha 1A/B adrenergic receptor antagonists |
US6911453B2 (en) * | 2001-12-05 | 2005-06-28 | Aventis Pharma Deutschland Gmbh | Substituted 4-phenyltetrahydroisoquinolinium, process for their preparation, their use as a medicament, and medicament containing them |
US6974803B2 (en) | 2001-12-06 | 2005-12-13 | Pfizer Inc | Pharmaceutical combination |
US6703405B2 (en) | 2001-12-22 | 2004-03-09 | Aventis Pharma Deutschland Gmbh | Substituted 4-phenyltetrahydroisoquinolinium salts, process for their preparation, their use as a medicament, and medicament containing them |
US20050113283A1 (en) | 2002-01-18 | 2005-05-26 | David Solow-Cordero | Methods of treating conditions associated with an EDG-4 receptor |
US20050261298A1 (en) | 2002-01-18 | 2005-11-24 | David Solow-Cordero | Methods of treating conditions associated with an Edg-7 receptor |
EP1676844A1 (en) | 2004-12-28 | 2006-07-05 | Laboratorios Del Dr. Esteve, S.A. | 5-HT7 receptor antagonists |
EP1483233A4 (en) | 2002-03-13 | 2005-12-21 | Univ Tennessee Res Corp | SUBSTITUTED TETRAHYDROISOQUINOLEINE COMPOUNDS, METHODS OF PREPARATION AND USE THEREOF |
SI1539673T1 (sl) | 2002-07-09 | 2008-02-29 | Lonza Ag | Postopek za pripravo N-monosubstituiranih beta-amino alkoholov |
CA2492019A1 (en) | 2002-08-13 | 2004-02-19 | Warner-Lambert Company Llc | Isoquinoline derivatives as matrix metalloproteinase inhibitors |
AU2003249531A1 (en) | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | Azaisoquinoline derivatives as matrix metalloproteinase inhibitors |
WO2004026225A2 (en) | 2002-09-20 | 2004-04-01 | Medisyn Technologies, Inc. | Therapeutic agents and corresponding treatments |
JP4465276B2 (ja) | 2002-10-16 | 2010-05-19 | イシス イノベイション リミテッド | アスパラギニルヒドロキシラーゼ及びその修飾物質 |
GB0224557D0 (en) | 2002-10-22 | 2002-11-27 | Glaxo Group Ltd | Novel compounds |
CA2505783A1 (en) | 2002-12-02 | 2004-06-17 | Pharmacia & Upjohn Company Llc | The use of 4-phenyl-substituted tetrahydroisoquinolines in the treatment of pain, migraine headaches and urinary incontinence |
AU2003283646A1 (en) | 2002-12-02 | 2004-06-23 | Pharmacia & Upjohn Company Llc | The use of aryl- and heteroaryl-substituted tetrahydroisoquinolines in the treatment of chronic and neuropathic pain, migraine headaches, and urge, stress and mixed urinary incontinence |
DE10303254B3 (de) | 2003-01-28 | 2004-09-23 | Johannes-Gutenberg-Universität Mainz | 3,3-Dimethyl-8-oxoisochinoline, Verfahren zu ihrer Herstellung, sie enthaltende pharmazeutische Zusammensetzungen und deren Verwendung |
US7388019B2 (en) | 2003-01-31 | 2008-06-17 | Merck & Co., Inc. | 3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
US7241775B2 (en) | 2003-03-24 | 2007-07-10 | Sanofi-Aventis Deutschland Gmbh | Composition, process of making, and medical use of substituted 4-phenyltetrahydroisoquinolines |
WO2004096774A1 (en) | 2003-05-01 | 2004-11-11 | Glaxo Group Limited | Acyl isoindoline derivatives and acyl isoquinoline derivatives as anti-viral agents |
US7459460B2 (en) | 2003-05-28 | 2008-12-02 | Bristol-Myers Squibb Company | Trisubstituted heteroaromatic compounds as calcium sensing receptor modulators |
WO2005002672A2 (en) | 2003-07-01 | 2005-01-13 | President And Fellows Of Harvard College | Sirt1 modulators for manipulating cells/organism lifespan/stress response |
WO2005014532A1 (en) | 2003-08-08 | 2005-02-17 | Transtech Pharma, Inc. | Aryl and heteroaryl compounds, compositions and methods of use |
CN1867331B (zh) | 2003-09-17 | 2010-05-26 | 美国政府健康及人类服务部 | 作为TNF-α调节剂的沙利度胺类似物 |
US7491794B2 (en) | 2003-10-14 | 2009-02-17 | Intermune, Inc. | Macrocyclic compounds as inhibitors of viral replication |
JP2007008816A (ja) | 2003-10-15 | 2007-01-18 | Ube Ind Ltd | 新規イソキノリン誘導体 |
WO2005054176A1 (en) | 2003-11-25 | 2005-06-16 | Eli Lilly And Company | Peroxisome proliferator activated receptor modulators |
AU2004312072B2 (en) | 2003-12-29 | 2011-06-23 | President And Fellows Of Harvard College | Compositions for treating or preventing obesity and insulin resistance disorders |
BRPI0507839A (pt) | 2004-02-18 | 2007-05-08 | Pfizer Prod Inc | derivados tetraidroisoquinolinil de quinazolina e isoquinolina |
CN1942186B (zh) | 2004-03-09 | 2010-10-06 | 国家卫生研究院 | 吡咯烷化合物 |
EA012389B1 (ru) | 2004-03-30 | 2009-10-30 | Интермун, Инк. | Макроциклические соединения в качестве ингибиторов вирусной репликации |
CN1988907B (zh) | 2004-06-01 | 2010-12-22 | 弗吉尼亚大学专利基金会 | 癌瘤及血管生成的双重小分子抑制剂 |
WO2006004722A2 (en) | 2004-06-30 | 2006-01-12 | Biomol Research Laboratories, Inc. | Compositions and methods for selectively activating human sirtuins |
ZA200701232B (en) * | 2004-07-15 | 2008-08-27 | Amr Technology Inc | Aryl-and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine and serotonin |
WO2006020145A2 (en) | 2004-07-19 | 2006-02-23 | The Johns Hopkins University | Flt3 inhibitors for immune suppression |
US7211585B2 (en) | 2004-08-18 | 2007-05-01 | Laboratorios Del Dr. Esteve, S.A. | 5-HT7 receptor antagonists |
US7211584B2 (en) | 2004-08-18 | 2007-05-01 | Laboratorios Del Dr. Esteve, S.A. | 5-HT7 receptor ligands |
DE102004046492A1 (de) | 2004-09-23 | 2006-03-30 | Sanofi-Aventis Deutschland Gmbh | Substituierte 4-Phenyltetrahydroisochinoline, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, sowie sie enthaltendes Medikament |
US20060111385A1 (en) | 2004-11-22 | 2006-05-25 | Molino Bruce F | Novel 4-phenyl substituted tetrahydroisoquinolines and therapeutic use thereof |
US20060111393A1 (en) | 2004-11-22 | 2006-05-25 | Molino Bruce F | 4-Phenyl substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine and serotonin |
US20060111394A1 (en) | 2004-11-22 | 2006-05-25 | Molino Bruce F | Aryl-and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine and serotonin |
DE602005026169D1 (de) | 2004-12-17 | 2011-03-10 | Janssen Pharmaceutica Nv | Tetrahydroisochinolinverbindungen zur behandlung von zns-erkrankungen |
US20070060589A1 (en) | 2004-12-21 | 2007-03-15 | Purandare Ashok V | Inhibitors of protein arginine methyl transferases |
AU2006206274A1 (en) | 2005-01-20 | 2006-07-27 | Sirtris Pharmaceuticals, Inc. | Use of sirtuin-activating compounds for treating flushing and drug induced weight gain |
KR20070107000A (ko) | 2005-02-15 | 2007-11-06 | 노보 노르디스크 에이/에스 | 3,4-디히드로-1h-이소퀴놀린-2-카르복실산5-아미노피리딘-2-일 에스테르 |
WO2006105440A2 (en) | 2005-03-30 | 2006-10-05 | Sirtris Pharmaceuticals, Inc. | Nicotinamide riboside and analogues thereof |
DE102005025625A1 (de) | 2005-06-01 | 2006-12-07 | Friedrich-Schiller-Universität Jena | Neue hochaffine Dopaminantagonisten zur Behandlung der Schizophrenie und Verfahren zu ihrer Herstellung |
EP1904069B1 (en) | 2005-07-15 | 2018-06-13 | Albany Molecular Research, Inc. | Aryl-and heteroaryl-substituted tetrahydrobenzazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin |
US7425633B2 (en) | 2005-08-26 | 2008-09-16 | National Health Research Institutes | Pyrrolidine compounds |
AU2006291234A1 (en) | 2005-09-14 | 2007-03-22 | Amgen Inc. | Conformationally constrained 3- (4-hydroxy-phenyl) - substituted-propanoic acids useful for treating metabolic disorders |
AR058065A1 (es) | 2005-09-27 | 2008-01-23 | Novartis Ag | Compuestos de carboxiamina y uso de los mismos.composiciones farmaceuticas. |
EA013907B1 (ru) | 2005-10-26 | 2010-08-30 | Мерк Сероно С.А. | Сульфонамидные производные и их применение для модулирования металлопротеаз |
CA2627426A1 (en) | 2005-11-11 | 2007-05-18 | Markus Boehringer | Carbocyclic fused cyclic amines as inhibitors of the coagulation factor xa |
WO2007098608A1 (en) | 2006-03-02 | 2007-09-07 | Chao-Jun Li | Chiral ligands, their preparation and uses thereof in assymetric reactions |
US8153674B2 (en) | 2006-03-29 | 2012-04-10 | Novartis Ag | Organic compounds |
JP5223083B2 (ja) | 2006-06-21 | 2013-06-26 | 国立大学法人京都大学 | 血管新生抑制剤 |
US7919598B2 (en) | 2006-06-28 | 2011-04-05 | Bristol-Myers Squibb Company | Crystal structures of SGLT2 inhibitors and processes for preparing same |
WO2008005368A2 (en) | 2006-06-30 | 2008-01-10 | Abbott Laboratories | Piperazines as p2x7 antagonists |
US8524757B2 (en) | 2006-07-04 | 2013-09-03 | Janssen Pharmaceutica Nv | Benzimidazole cannabinoid agonists bearing a substituted heterocyclic group |
ES2576477T3 (es) | 2006-08-07 | 2016-07-07 | Janssen Pharmaceutica Nv | Proceso para la preparación de derivados de 1,2,3,4-tetrahidroisoquinolina sustituidos |
US8993593B2 (en) | 2006-08-23 | 2015-03-31 | Valeant Pharmaceuticals International | N-(4-(6-fluoro-3,4-dihydroisoquinolin-2(1H)-yl)-2,6-dimethylphenyl)-3,3-dimethylbutanamide as potassium channel modulators |
CA2661462C (en) | 2006-08-23 | 2015-09-29 | Valeant Pharmaceuticals International | Derivatives of 4-(n-azacycloalkyl) anilides as potassium channel modulators |
DE102006046922B3 (de) | 2006-09-27 | 2007-11-15 | Julius-Maximilians-Universität Würzburg | Biofilm-hemmende Wirkung sowie anti-infektive Aktivität N,C-verknüpfter Arylisochinoline, deren pharmazeutischen Zusammensetzung und deren Verwendung |
NZ576234A (en) | 2006-11-06 | 2011-06-30 | Supergen Inc | Imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine derivatives and their use as protein kinase inhibitors |
KR20090127307A (ko) | 2007-03-01 | 2009-12-10 | 얀센 파마슈티카 엔.브이. | 히스타민 h3 수용체 조절제로서의 테트라하이드로이소퀴놀린 화합물 |
US7321064B1 (en) | 2007-03-08 | 2008-01-22 | Cedarburg Pharmaceuticals, Inc. | Preparation of amides of retinoic acid via mixed anhydride and mixed carbonate intermediates |
JP2010526825A (ja) | 2007-05-10 | 2010-08-05 | エーエムアール テクノロジー インコーポレイテッド | アリール置換およびヘテロアリール置換テトラヒドロベンゾ−1,4−ジアゼピンならびにノルエピネフリン、ドーパミンおよびセロトニンの再取り込みを遮断するためのその使用 |
JP5566282B2 (ja) | 2007-05-10 | 2014-08-06 | アルバニー モレキュラー リサーチ, インコーポレイテッド | アリールオキシ置換およびヘテロアリールオキシ置換テトラヒドロベンゾアゼピンならびにノルエピネフリン、ドーパミンおよびセロトニンの再取り込みを遮断するためのその使用 |
WO2008144305A1 (en) | 2007-05-18 | 2008-11-27 | Janssen Pharmaceutica N.V. | Diaryl-substituted tetrahydroisoquinolines as histamine h3 receptor and serotonin transporter modulators |
US20090069374A1 (en) | 2007-06-06 | 2009-03-12 | Phil Skolnick | Novel 1-Heteroaryl-3-Azabicyclo[3.1.0]Hexanes, Methods For Their Preparation And Their Use As Medicaments |
AR071997A1 (es) | 2008-06-04 | 2010-07-28 | Bristol Myers Squibb Co | Forma cristalina de 6-((4s)-2-metil-4-(2-naftil)-1,2,3,4-tetrahidroisoquinolin-7-il)piridazin-3-amina |
US9156812B2 (en) | 2008-06-04 | 2015-10-13 | Bristol-Myers Squibb Company | Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine |
RU2561104C2 (ru) | 2008-06-20 | 2015-08-20 | Дженентек, Инк. | Триазолопиридиновые соединения-ингибиторы jak и способы |
TWI453207B (zh) | 2008-09-08 | 2014-09-21 | Signal Pharm Llc | 胺基三唑并吡啶,其組合物及使用其之治療方法 |
CN102638982B (zh) | 2009-05-12 | 2015-07-08 | 百时美施贵宝公司 | (S)-7-([1,2,4]三唑并[1,5-a]吡啶-6-基)-4-(3,4-二氯苯基)-1,2,3,4-四氢异喹啉的晶型及其用途 |
KR20120034644A (ko) | 2009-05-12 | 2012-04-12 | 알바니 몰레큘라 리써치, 인크. | 아릴, 헤테로아릴, 및 헤테로사이클 치환된 테트라하이드로이소퀴놀린 및 이의 용도 |
CA2760837C (en) | 2009-05-12 | 2018-04-03 | Albany Molecular Research, Inc. | 7-([1,2,4]triazolo[1,5-.alpha.]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydroisoquinoline and use thereof |
MX2012013196A (es) | 2010-05-12 | 2013-03-22 | Abbvie Inc | Inhibidores de pirrolopiridina y pirrolopirimidina de cinasas. |
EP2606049A4 (en) | 2010-08-17 | 2014-01-08 | Albany Molecular Res Inc | 2,5-METHANO- AND 2,5-ETHANO-TETRAHYDROBENZAZEPINE DERIVATIVES AND USES THEREOF FOR BLOCKING NOREPINEPHRINE, DOPAMINE, AND SEROTONIN REUPTAKE |
US20160022675A1 (en) | 2013-03-14 | 2016-01-28 | Bristol-Myers Squibb Company | Processes for preparing tetrahydroisoquinolines |
-
2005
- 2005-07-15 ZA ZA200701232A patent/ZA200701232B/xx unknown
- 2005-07-15 CA CA2573271A patent/CA2573271C/en active Active
- 2005-07-15 EP EP05793999.3A patent/EP1778639B1/en active Active
- 2005-07-15 JP JP2007521686A patent/JP5007226B2/ja active Active
- 2005-07-15 MX MX2007000428A patent/MX2007000428A/es active IP Right Grant
- 2005-07-15 GE GEAP20059847A patent/GEP20094640B/en unknown
- 2005-07-15 RU RU2007105596A patent/RU2388751C2/ru not_active IP Right Cessation
- 2005-07-15 US US11/183,066 patent/US7541357B2/en active Active
- 2005-07-15 UA UAA200701576A patent/UA91341C2/ru unknown
- 2005-07-15 WO PCT/US2005/025193 patent/WO2006020049A2/en active Application Filing
- 2005-07-15 NZ NZ552397A patent/NZ552397A/en not_active IP Right Cessation
- 2005-07-15 BR BRPI0513359-9A patent/BRPI0513359A/pt not_active IP Right Cessation
- 2005-07-15 KR KR1020077003549A patent/KR101412339B1/ko active IP Right Grant
- 2005-07-15 US US11/183,102 patent/US20060063766A1/en not_active Abandoned
- 2005-07-15 CN CN200580030990.2A patent/CN101119969B/zh active Active
- 2005-07-15 CN CN201410074721.7A patent/CN103880827B/zh active Active
- 2005-07-15 AU AU2005274927A patent/AU2005274927B2/en not_active Ceased
- 2005-07-15 KR KR1020137001614A patent/KR101389246B1/ko active IP Right Grant
-
2006
- 2006-12-26 IL IL180349A patent/IL180349A/en not_active IP Right Cessation
-
2007
- 2007-02-15 NO NO20070877A patent/NO20070877L/no not_active Application Discontinuation
-
2008
- 2008-10-16 US US12/252,823 patent/US8227486B2/en active Active
-
2009
- 2009-04-02 US US12/417,598 patent/US8236796B2/en active Active
-
2012
- 2012-04-05 JP JP2012086151A patent/JP5552137B2/ja active Active
- 2012-07-02 US US13/540,446 patent/US8741901B2/en active Active
-
2014
- 2014-05-02 US US14/268,753 patent/US9085531B2/en active Active
- 2014-12-23 HK HK14112805.4A patent/HK1199253A1/xx not_active IP Right Cessation
-
2015
- 2015-06-12 US US14/737,897 patent/US9499531B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20070877L (no) | Aryl- og heteroaryl substituerte tetrahydroisoquinoliner og bruk derav for a blokkere gjenopptak av norepinefrin, dopamin og serotonin | |
ES2250689T3 (es) | 1h-pirido(4,3-b)indoles terapeuticos. | |
AU633051B2 (en) | Substituted pyrroles | |
CA2933767C (en) | Novel 3,4-disubstituted-1h-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7h-pyrrolo[2,3-c]pyridazines as lrrk2 inhibitors | |
AU2012205687B2 (en) | Heteroaryl compounds and methods of use thereof | |
CO6251238A2 (es) | Tetrahidrobenzo-1,4-diacepinas arilo - y heteroarilo - sustituidas y su uso para bloquear la recaptacion de norepinefrina dapamina y serotanina | |
US7544697B2 (en) | Pyrazolopyridines and analogs thereof | |
RU2007121768A (ru) | Би- и трициклически замещенные фенилметаноны в качестве ингибиторов переносчика глицина 1 (glyt-1) для лечения болезни альцгеймера | |
FR3052452A1 (no) | ||
KR0173450B1 (ko) | 치환된 피롤, 이의 제조방법 및 이를 함유하는 의약품 | |
EP1831226A2 (en) | CHIRAL FUSED 1,2 IMIDAZO 4,5-c RING COMPOUNDS | |
CA2752073A1 (en) | Histamine h3 inverse agonists and antagonists and methods of use thereof | |
TW200918071A (en) | Agent for prevention and/or treatment of skin diseases | |
AR037683A1 (es) | Compuestos derivados de heteroaril nitrilos, metodos para su preparacion, composiciones farmaceuticas que los comprenden y uso de dichos compuestos en la preparacion de medicamentos | |
JPH08502056A (ja) | 5−ht▲下4▼アンタゴニスト | |
WO2012114252A1 (en) | Novel indole and pyrrolopyridine amides | |
JP6542900B2 (ja) | 抗肺結核症のニトロイミダゾール誘導体 | |
AU2017245318A1 (en) | Heteroaryl compounds and methods of use thereof | |
CA2136913A1 (en) | Tetracyclic condensed heterocyclic compounds, their production and use | |
WO2006051410A1 (en) | Azabenzoxazoles for the treatment of cns disorders | |
US10888853B2 (en) | Cinchonium betaine catalysts and methods of using same | |
US11148125B2 (en) | Catalysts for olefin isomerization | |
CN106928097B (zh) | 化合物、其制备方法及其在制备药物中的用途 | |
CA3092149C (en) | Indolizine compound, preparation method and use thereof | |
WO2024073502A1 (en) | Heterocyclic compounds as e3 ligase inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
CHAD | Change of the owner's name or address (par. 44 patent law, par. patentforskriften) |
Owner name: BRISTOL-MYERS SQUIBB CO,US |
|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |